Deerfield group reports 4.34% CalciMedica (CALC) stake via warrants

Rhea-AI Filing Summary

CalciMedica Inc. (CALC) received an amended Schedule 13G from investment entities affiliated with Deerfield and James E. Flynn. The filing reports beneficial ownership of 653,253 shares of common stock, all issuable upon exercise of warrants held by Deerfield Partners, L.P.

The position represents 4.34% of CalciMedica’s common stock. All reporting persons disclose zero sole voting or dispositive power and shared voting and dispositive power over the same 653,253 shares. They also certify the holdings were not acquired to change or influence control of CalciMedica, characterizing the stake as passive.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CalciMedica Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

38942Q202

(CUSIP Number)

02/06/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 38942Q202

1

Names of Reporting Persons

Deerfield Mgmt, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 653,253.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 653,253.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

653,253.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.34 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprised of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

SCHEDULE 13G

CUSIP No. 38942Q202

1

Names of Reporting Persons

Deerfield Management Company, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 653,253.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 653,253.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

653,253.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.34 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

SCHEDULE 13G

CUSIP No. 38942Q202

1

Names of Reporting Persons

Deerfield Partners, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 653,253.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 653,253.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

653,253.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.34 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable).

SCHEDULE 13G

CUSIP No. 38942Q202

1

Names of Reporting Persons

James E. Flynn

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 653,253.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 653,253.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

653,253.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.34 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CalciMedica Inc.
(b)	Address of issuer's principal executive offices: 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037
Item 2.
(a)	Name of person filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P.
(b)	Address or principal business office or, if none, residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
(c)	Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 38942Q202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Deerfield Mgmt, L.P. - 653,253 shares Deerfield Management Company, L.P. - 653,253 shares Deerfield Partners, L.P. - 653,253 shares James E. Flynn - 653,253 shares
(b)	Percent of class: Deerfield Mgmt, L.P. - 4.34% Deerfield Management Company, L.P. - 4.34% Deerfield Partners, L.P. - 4.34% James E. Flynn - 4.34%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: All Reporting Persons - 0
	(ii) Shared power to vote or to direct the vote: Deerfield Mgmt, L.P. - 653,253 Deerfield Management Company, L.P. - 653,253 Deerfield Partners, L.P. - 653,253 James E. Flynn - 653,253
	(iii) Sole power to dispose or to direct the disposition of: All Reporting Persons - 0
	(iv) Shared power to dispose or to direct the disposition of: Deerfield Mgmt, L.P. - 653,253 Deerfield Management Company, L.P. - 653,253 Deerfield Partners, L.P. - 653,253 James E. Flynn - 653,253
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit B
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deerfield Mgmt, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	02/06/2026

Deerfield Management Company, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	02/06/2026

Deerfield Partners, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	02/06/2026

James E. Flynn

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	02/06/2026

Exhibit Information

Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

FAQ

What ownership stake in CalciMedica (CALC) does Deerfield report?

Deerfield-affiliated entities and James E. Flynn report beneficial ownership of 653,253 CalciMedica common shares, all issuable upon exercise of warrants. This position represents 4.34% of the company’s common stock, according to the amended Schedule 13G filing.

How are Deerfield’s CalciMedica (CALC) shares held according to the filing?

The filing states the reported 653,253 CalciMedica shares are issuable upon exercise of warrants, subject to applicable adjustments. These warrants are held by Deerfield Partners, L.P., with Deerfield Mgmt, L.P. as general partner and Deerfield Management Company, L.P. as investment adviser.

Is Deerfield’s CalciMedica (CALC) position classified as passive or activist?

The reporting persons certify the securities were not acquired and are not held to change or influence control of CalciMedica. This language indicates a passive investment intent under the Schedule 13G framework, rather than an activist control-oriented position.

Which entities and individuals report ownership of CalciMedica (CALC) shares?

The Schedule 13G/A lists Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn as reporting persons. Each reports beneficial ownership of the same 653,253 warrant-share equivalent, equal to 4.34% of CalciMedica’s common stock.

What voting and dispositive powers do Deerfield and Flynn have over CalciMedica (CALC) shares?

All reporting persons disclose no sole voting or dispositive power over CalciMedica shares. Each reports shared voting power and shared dispositive power with respect to 653,253 shares, reflecting the coordinated control of the warrant position.

Why does the CalciMedica (CALC) Schedule 13G/A mention ownership of 5 percent or less?

Item 5 indicates ownership of 5 percent or less of CalciMedica’s common stock. The reported 4.34% stake reflects a sub‑5% holding, which still requires reporting but is below the typical 5% threshold often associated with larger significant holders.